Pfizer (PFE.US) and Germany's BioNTech (BNTX.US) shares rose 3.9% and 6.5% respectively in premarket after British officials authorized their COVID-19 vaccine for emergency use. UK government is reportedly the first in the world to formally approve the Pfizer-BioNTech shot for widespread use. British officials said the vaccine will be rolled out from next week with elderly people in care homes and medical workers first in line. British Health Secretary Matt Hancock said Britain expects to begin receiving the first shipment of 800,000 doses “within days,'' and people will begin receiving shots as soon as the National Health Service gets the vaccine. British regulators also are considering another vaccine developed by AstraZeneca (AZN.UK) and Oxford University.
Pfizer (PFE.US) stock rose to around $40.75 in today's pre-market trading after UK authorized its coronavirus vaccine for emergency use. The closest resistance level can be found at $41.96. Source: xStation5
BioNTech (BNTX.US) shares jumped to around $121.87 in today's pre-market trading. The closest resistance level is located at $128.07. Source: xStation5
UK100 - London's blue-chip index outperforms regional peers during today's session on upbeat vaccine news. Index bounced off the 50 SMA (green line) and broke above the upper limit of the downward channel. If the current sentiment prevails, the upward move may accelerate towards 6471 pts. Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.